
    
      Eligible patients who signed the informed consent will randomly assigned to one of 3 groups;
      group 1 (control), group 2 (tamsulosin) and group 3 (Solifenacin). Ureteral stent symptom
      questionnaire (USSQ) will be used to compare health related quality of life scores.
    
  